Anti-C5a antibodies
US-9371378-B1 · Jun 21, 2016 · US
Nucleic acids encodng anti-C5A antibodies
US9434784B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9434784-B1 |
| Application number | US-201615161893-A |
| Country | US |
| Kind code | B1 |
| Filing date | May 23, 2016 |
| Priority date | Apr 30, 2010 |
| Publication date | Sep 6, 2016 |
| Grant date | Sep 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45. 2. A nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO:42. 3. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively. 4. A nucleic acid encoding a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO:45. 5. A nucleic acid encoding a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the light chain variable region comprising the amino acid sequence depicted in SEQ ID NO:42. 6. A nucleic acid encoding heavy and light chain variable regions of an antibody, or antigen-binding fragments thereof, that bind to human C5a, wherein the heavy and light chain variable regions comprise the amino acid sequences depicted in SEQ ID NOs:45 and 42, respectively. 7. A nucleic acid encoding a heavy chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49. 8. A nucleic acid encoding a light chain of an antibody, or antigen-binding fragment thereof, that binds to C5a, wherein the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40. 9. A nucleic acid encoding a heavy chain and a light chain of an antibody, or antigen-binding fragment thereof, that binds to human C5a, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO: 49 and the light chain comprises the amino acid sequence depicted in SEQ ID NO: 40. 10. An expression vector comprising the nucleic acid according to claim 1 . 11. A cell comprising the expression vector according to claim 10 . 12. An expression vector comprising the nucleic acid according to claim 2 . 13. A cell comprising the expression vector according to claim 12 . 14. An expression vector comprising the nucleic acid according to claim 3 . 15. A cell comprising the expression vector according to claim 14 . 16. An expression vector comprising the nucleic acid according to claim 4 . 17. A cell comprising the expression vector according to claim 16 . 18. An expression vector comprising the nucleic acid according to claim 5 . 19. A cell comprising the expression vector according to claim 18 . 20. An expression vector comprising the nucleic acid according to claim 6 . 21. A cell comprising the expression vector according to claim 20 . 22. An expression vector comprising the nucleic acid according to claim 7 . 23. A cell comprising the expression vector according to claim 22 . 24. An expression vector comprising the nucleic acid according to claim 8 . 25. A cell comprising the expression vector according to claim 24 . 26. An expression vector comprising the nucleic acid according to claim 9 . 27. A cell comprising the expression vector according to claim 26 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for immunological or allergic disorders · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Antihyperlipidemics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9434784B1 cover?
- The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus …
- Who is the assignee on this patent?
- Alexion Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).